Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 May 2015
At a glance
- Drugs Sorafenib (Primary) ; Doxorubicin
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms SoraDox
- 31 Mar 2014 Planned end date changed from 1 Oct 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 31 Mar 2014 Trial status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 25 Jan 2013 Planned end date changed from 1 Sep 2012 to 1 Oct 2014 as reported by ClinicalTrials.gov.